Loading
Hcmed: what insiders have been doing
Only a handful of insider records exist for Hcmed, the last one from 26 January 2026, too few to describe a trend. Every figure here comes from the filings published by TWSE / TPEx (MOPS) and describes the past, not future prices; it is not investment advice.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 21,085 of 23,476 companies
22.4
score / 100
Value22
Quality23
FCF yld-4.7%
Earn yld-4.7%
EV/EBITDA·
ROE-30%
Gross mgn25%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NT$74
Analyst consensus
1 analystsNT$115Target NT$115(+56%)NT$115
Income statement
RevenueNT$100.2M
Gross profitNT$24.9M25% margin
EBITDA-NT$104M-104% margin
Net income-NT$126.1M-114.1% margin
Valuation
P/Book5.0x
Beta1.50
Balance sheet & cash
Market capNT$2.7B
Total debtNT$111.9M
Free Cash Flow-NT$124.2M
Debt / Equity20%
Profitability & ownership
ROE-30.1%
ROA-15.7%
% insiders36.4%
% institutions8.4%
Last declaration on 26 January 2026
About Hcmed
心誠鎂 is a company listed on the XTAI market, specializing in magnesium production. It focuses on innovation and sustainability in its manufacturing processes.